The IMA Group on April 11 announced that it entered into an agreement to acquire Accelemed Research Institute.
The acquisition expands The IMA Group’s depth in multi-therapeutic clinical trial sites focused on cardiometabolic and GI diseases such as non-alcoholic steatohepatitis, obesity, high cholesterol and diabetes. The financial terms were not disclosed.
Accelemed Research Institute operates out of Austin, Texas and conducts clinical trials to allow safety and efficacy data to be collected for new drugs, medical devices or treatment techniques.
The IMA Group provides government workers with medical, psychological and related evaluations, as well as ancillary services. The company assists payers with case management and occupational health management solutions and offers clinical research firms access to new advances in pharmacology and biotechnology for research subjects.
According to data captured in the LevinPro HC database, this transaction represents the seventh clinical trials transaction of the year. Previously in 2023, The IMA Group also acquired Clinical Trials of America, a multi-therapeutic clinical trials company based in Monroe, Louisiana.
